The company has reported net sales of $2.07 billion for the second quarter of 2009 compared to $2.02 billion for the corresponding period of 2008.

Boston Scientific has reported a net income of $145 million, or $0.10 per diluted share for the first half of 2009, compared to $420 million, or $0.28 per diluted share, for the first half of 2008.

The company has reported net sales of $4.08 billion for the first half of 2009 compared to $4.07 billion for the same period of 2008.

Ray Elliott, president and CEO of Boston Scientific, said: "I am excited about joining the Boston Scientific team and to help report a very good quarter. We delivered sales and earnings at the high end of our guidance range with almost all businesses and regions reporting solid results.

"The performance of our two largest businesses was particularly impressive, with cardiovascular achieving mid-teens growth in drug-eluting stent sales and cardiac rhythm management recording its fifth consecutive quarter of double-digit growth in the US."

A service of YellowBrix, Inc.